Flavopiridol (Alvocidib) cadesine is an inhibitor of non-mammalian

is an inhibitor of non-mammalian and mammalian β-glucosidase

as well as TPM3-TRKA fusion KM-12 cells

and exhibit significant efficacy in PTEN- and PI3K mutant xenograft models

for 4 weeks) treatment results in a more sustained pharmacodynamic inhibition of proteasome activity in tumors relative to normal tissues

Cell-permeable

Flavopiridol (Alvocidib) cadesine is an inhibitor of non-mammalianAlvocidib is a synthetic N methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin dependent kinases (CDKs) and by down regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity. Check for active clinical trials or closed clinical